June 24, 2020 / 5:07 AM / 13 days ago

BRIEF-Relief Therapeutics And Neurorx To Fast Track Designation Granted By FDA To RLF-100 For Treatment Of Respiratory Distress In COVID-19

June 24 (Reuters) - RELIEF THERAPEUTICS Holding SA:

* NEURORX AND RELIEF THERAPEUTICS ANNOUNCE FAST TRACK DESIGNATION GRANTED BY FDA TO RLF-100 (AVIPTADIL) FOR TREATMENT OF RESPIRATORY DISTRESS IN COVID-19 Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below